<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03166735</url>
  </required_header>
  <id_info>
    <org_study_id>1386-0004</org_study_id>
    <secondary_id>2016-000499-83</secondary_id>
    <nct_id>NCT03166735</nct_id>
  </id_info>
  <brief_title>Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH</brief_title>
  <official_title>A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Pharmacodynamics, Safety and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is the proof of mechanism and support of dose finding,
      together with the safety evaluation in patients with clinical evidence of NASH.

      To gain further insight into clinical effects of AOC3 inhibition on NASH further exploratory
      analyses of biomarkers related to NASH and liver fibrosis will be performed. This will
      include the effect of BI 1467335 on reduction of secondary biomarker endpoints (ALT, AST, AP,
      γ-GT and CK18 fragments). Safety will be assessed throughout the study to provide key
      information regarding the use of BI 1467335 in patients with NASH.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 6, 2017</start_date>
  <completion_date type="Anticipated">April 12, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma amine oxidase copper-containing 3 (AOC3) activity relative to baseline in percent, 24 h post dose,</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with adverse reactions</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative ALT change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative AST change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative AP change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative Gamma-GT change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative caspase cleaved cytokeratin 18 (M30) change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative total cytokeratin 18 (M65) change from baseline</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">147</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>BI 1467335 dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1467335 dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1467335 dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1467335 dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1467335</intervention_name>
    <description>once daily</description>
    <arm_group_label>BI 1467335 dose 1</arm_group_label>
    <arm_group_label>BI 1467335 dose 2</arm_group_label>
    <arm_group_label>BI 1467335 dose 3</arm_group_label>
    <arm_group_label>BI 1467335 dose 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Clinical evidence of NASH defined as a. histological evidence of NASH (no more than 3
             years prior to screening) OR b. clinical imaging results suggestive of NASH (no more
             than 3 years prior to screening) OR within the screening phase, imaging procedures
             performed as per local standard) i. evidence of hepatic steatosis &gt;5% measured by the
             MRI-PDFF) or assessed as moderate to severe steatosis (raised echogenicity of the
             liver parenchyma) by ultrasound AND ii. evidence of liver fibrosis defined as mean
             stiffness &gt; 3.64 kPa as measured by the MRE protocol or mean stiffness &gt; 7.2 kPa as
             measured by ultrasound based transient elastography (Fibroscan®)

          -  Increased ALT defined as a. ALT &gt;1.5 ULN at screening and ALT &gt;1.25 ULN in a local lab
             within 1 week to 3 months prior screening OR b. Historic ALT &gt; 1.25 ULN more than 3
             months prior to screening and two consecutive ALT &gt; 1.5xULN must be confirmed at least
             1 week apart within the screening period

          -  Age ≥ 18 and ≤75 years at screening

          -  BMI ≥25kg/m2 and &lt;45kg/m2 at screening

          -  Stable body weight defined as less than 5% change in body weight in the 3 months prior
             to screening while being treated with the standard of care and not treated with
             anti-obesity medication at screening.

          -  Treatment with Antidiabetic concomitant medication including any insulin regimen needs
             to be stable for 3 months, and treatment with vitamin E needs to be stable for 6
             months prior to informed consent and expected to be stable throughout the trial. All
             other concomitant medication has to be stable for at least 4 weeks prior screening.
             Concomitant medications taken to treat acute conditions (e.g. headache, sinusitis) for
             a short period (&lt; 7 days) are permissible, if not otherwise prohibited.

          -  For female patients: Women of childbearing potential* can be randomized after a
             negative pregnancy test and under adequate contraception with two methods, of which at
             least one is highly effective, during the trial.* A woman is considered of
             childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming
             post-menopausal unless permanently sterile. Permanent sterilisation methods include
             hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is
             NOT a method of permanent sterilisation. A postmenopausal state is defined as no
             menses for 12 months without an alternative medical cause.

          -  Signed and dated written informed consent in accordance with GCP and local legislation
             prior to admission to the trial.

        Exclusion criteria:

          -  Current or history of significant alcohol consumption (defined as intake of &gt;210g/week
             in males and &gt;140g/week in females on average over a consecutive period of more than 3
             months) or inability to reliably quantify alcohol consumption based on investigator
             judgement.

          -  Prior participation in an interventional NASH trial 6 months before baseline or 5
             times halflife of the investigational drug, whichever is longer.

          -  Prior or planned bariatric surgery during study conduct, except gastric-band surgery
             more than 2 years prior to screening (including adjustments) with a stable body weight
             within the last 12 months.

          -  Use of drugs historically associated with liver injury, hepatic steatosis or
             steatohepatitis in the 4 weeks prior to screening.

          -  History of liver cirrhosis (fibrosis stage 4), or hepatic decompensation (e.g.
             ascites, hepatic encephalopathy, variceal bleeding, etc.) or history of other forms of
             chronic liver disease (for example Hepatitis B, Hepatitis C, autoimmune liver disease,
             primary biliary sclerosis, primary sclerosing cholangitis, Wilsons disease,
             hemochromatosis, A1At deficiency, history of liver transplantation).

          -  Active known chronic or relevant acute infections, such as HIV (Human Immunodeficiency
             Virus), \viral hepatitis, or tuberculosis. QuantiFERON® TB test and HBs Ag test will
             be performed during screening. Patients with a positive test result may participate in
             the study if further work up (according to local practice/guidelines) establishes
             conclusively that the patient has no evidence of active infection.

          -  Solid liver lesions other than haemangiomas.

             -- Suspicion or diagnosis or history of hepatocellular carcinoma (HCC)

          -  eGFR &lt;60ml/min/1.73m2 at screening (CKD-EPI formula).

          -  ALT &gt;5.0 ULN at screening.

          -  Platelet count &lt; 150.000/μL

          -  Bilirubin level &gt; ULN (except for known Gilbert´s disease with a conjugated bilirubin
             of &lt; 0.3 mg/dL))

          -  Uncontrolled diabetes defined as an HbA1c ≥9.5% in the 3 months prior to or at
             screening.

          -  Diagnosis of a serious or unstable disease including hepatic (other than NASH), renal,
             gastroenterologic, respiratory, cardiovascular (including ischemic heart disease),
             endocrinologic, neurologic , psychiatric, immunologic, or hematologic disease and
             other conditions that, in the clinical judgment of the investigator, are likely to
             interfere with the analyses of safety and efficacy in this study. Patients with an
             expected life expectancy of less than 2 years are also excluded.

          -  Major surgery (major according to the investigator's assessment) performed within 12
             weeks prior to randomisation or planned during study conduct, e.g. hip replacement.

          -  Any documented active or suspected malignancy or history of malignancy within 5 years
             prior to screening, except appropriately treated basal cell carcinoma of the skin or
             in situ carcinoma of uterine cervix.

          -  Patients who must or wish to continue the intake of restricted medications or any drug
             considered likely to interfere with the safe conduct of the trial.

          -  Previous randomisation in this trial.

          -  Currently enrolled in another investigational device or drug study, or less than 30
             days since ending another investigational device or drug study(s), or receiving other
             investigational treatment(s).

          -  Chronic drug abuse or any condition that, in the investigator's opinion, makes them an
             unreliable study subject or unlikely to complete the trial.

          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.

          -  Patients with Wolff-Parkinson-White Syndrome, baseline QTc &gt; 450 ms, family history of
             long QT, or on medication prolonging QT time at screening or planned initiation during
             the trial.

          -  Any other clinical condition that, in the opinion of the investigator, would
             jeopardize patient safety while participating in this clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern California Research Center</name>
      <address>
        <city>Coronado</city>
        <state>California</state>
        <zip>92118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Hassanein</last_name>
      <phone>+001 (616) 522-0330</phone>
      <email>thassanein@livercenters.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rohit Loomba</last_name>
      <phone>+001 (858) 246-2301</phone>
      <email>roloomba@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Overcash</last_name>
      <phone>+001 (619) 567-1550</phone>
      <email>sovercash@estudysite.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Frias</last_name>
      <phone>+001 (213) 413-1800</phone>
      <email>juan.frias@nritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>eStudySite</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Florida Research Institute</name>
      <address>
        <city>Lakewood Ranch</city>
        <state>Florida</state>
        <zip>34211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy Neff</last_name>
      <phone>+001 (941) 216-4836</phone>
      <email>Guy.neffresearch@fdhs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rutgers Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinod Rustgi</last_name>
      <phone>+001 (732) 235-5662</phone>
      <email>vr262@rwjms.rutgers.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bernstein</last_name>
      <phone>+001 (516) 562-1688</phone>
      <email>dbernste@northwell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfred Barritt</last_name>
      <phone>+001 (919) 843-4558</phone>
      <email>Sid_barritt@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manal Abdelmalek</last_name>
      <phone>+001 (919) 684-8356</phone>
      <email>manal.abdelmalek@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diabetes and Endocrinology Consultants, PC</name>
      <address>
        <city>Morehead City</city>
        <state>North Carolina</state>
        <zip>28557</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Lucas</last_name>
      <phone>+001 (252) 222-5700</phone>
      <email>jeannie.lucas@lucasresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dallas Diabetes and Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julio Rosenstock</last_name>
      <phone>+001 (972) 566-7799</phone>
      <email>juliorosenstock@dallasdiabetes.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pinnacle Clinical Research</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harrison</last_name>
      <phone>+001 (210) 614-1234</phone>
      <email>Stephenharrison87@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Lawitz</last_name>
      <phone>+001 (210) 253-3426</phone>
      <email>lawitz@txliver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Sanyal</last_name>
      <phone>+001 (804) 828-4060</phone>
      <email>Arun.sanyal@vcuhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edegem - UNIV UZ Antwerpen</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sven Francque</last_name>
      <phone>+ 32 3 821 45 72</phone>
      <email>sven.francque@uza.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Maria Middelares</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Van Steenkiste</last_name>
      <phone>+32 (0)9 246 71 40</phone>
      <email>Christophe.VanSteenkiste@AZMMSJ.BE</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Len Verbeke</last_name>
      <phone>+32 (0)16 34 86 00</phone>
      <email>len.verbeke@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Delwaide</last_name>
      <phone>+32 4 366 72 56</phone>
      <email>jean.delwaide@chu.ulg.ac.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Congly</last_name>
      <phone>403-592-5076</phone>
      <email>secongly@ucalgary.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Liver and Intestinal Research Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1H2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edward Tam</last_name>
      <phone>604 876-5122</phone>
      <email>etam@laircentre.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keyur Patel</last_name>
      <phone>416 340 3015</phone>
      <email>keyur.patel@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6H 3M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdy ElKhashab</last_name>
      <phone>416-652-0606</phone>
      <email>melkashabmd@yahoo.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Mathurin</last_name>
      <phone>+33 (0)3 20 44 55 97</phone>
      <email>philippe.mathurin@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP St Joseph</name>
      <address>
        <city>Marseille</city>
        <zip>13285</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Bourlière</last_name>
      <phone>+33 (0)4 91 80 68 78</phone>
      <email>mbourliere@hopital-saint-joseph.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP La Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vlad Ratziu</last_name>
      <phone>+33 (0)1 42 16 10 35</phone>
      <email>vlad.ratziu@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, AöR</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Tacke</last_name>
      <phone>+49 (241) 8085660</phone>
      <email>ftacke@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen AöR</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Heinrich Wedemeyer</last_name>
      <phone>+49 (201) 723-0</phone>
      <email>heiner.wedemeyer@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tania Welzel</last_name>
      <phone>+49 (69) 630187769</phone>
      <email>tania.welzel@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln (AöR)</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Goeser</last_name>
      <phone>+49 (221) 4784470</phone>
      <email>Tgoeser-studien@uk-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörn Schattenberg</last_name>
      <phone>+49 (6131) 176831</phone>
      <email>Joern.Schattenberg@unimedizin-mainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Geier</last_name>
      <phone>+49 (931) 20140170</phone>
      <email>geier_A2@ukw.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St James's Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>8</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Norris</last_name>
      <phone>00353 142 84512</phone>
      <email>SNorris@STJAMES.IE</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ger Koek</last_name>
      <phone>+31(0) 43-3875021</phone>
      <email>gh.koek@mumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Drenth</last_name>
      <phone>+31 24 3613999</phone>
      <email>joost.drenth@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Augustin</last_name>
      <phone>+34932746240</phone>
      <email>salva.augustin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier García Samaniego</last_name>
      <phone>+34917276990</phone>
      <email>javiersamaniego@telefonica.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raúl Andrade Bellido</last_name>
      <phone>+34951032563</phone>
      <email>andrade@uma.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Crespo García</last_name>
      <phone>+34942213106</phone>
      <email>javiercrespo1991@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Romero</last_name>
      <phone>+34955012065</phone>
      <email>mromerogomez@us.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moises Diago</last_name>
      <phone>+34963181800 ext.437341</phone>
      <email>moisesdiagom@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip Newsome</last_name>
      <phone>0121 415 8700</phone>
      <email>P.N.Newsome@bham.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nick Stern</last_name>
      <phone>0151 529 2814</phone>
      <email>Nick.stern@aintree.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaun Greer</last_name>
      <phone>0161 901 2676/0161 276 4884</phone>
      <email>Shaun.Greer@mft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke on Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Brind</last_name>
      <phone>01782 674637</phone>
      <email>Alison.brind@uhnm.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2017</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

